Synthesis of Potential Haptens with Morphine Skeleton and Determination of Protonation Constants.
N-demethylation
acid-base properties
hapten
immunotherapy
microspeciation
morphine skeleton
nor-compounds
protonation state
vaccine
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
02 Sep 2020
02 Sep 2020
Historique:
received:
07
08
2020
revised:
24
08
2020
accepted:
01
09
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Vaccination could be a promising alternative warfare against drug addiction and abuse. For this purpose, so-called haptens can be used. These molecules alone do not induce the activation of the immune system, this occurs only when they are attached to an immunogenic carrier protein. Hence obtaining a free amino or carboxylic group during the structural transformation is an important part of the synthesis. Namely, these groups can be used to form the requisite peptide bond between the hapten and the carrier protein. Focusing on this basic principle, six nor-morphine compounds were treated with ethyl acrylate and ethyl bromoacetate, while the prepared esters were hydrolyzed to obtain the
Identifiants
pubmed: 32887468
pii: molecules25174009
doi: 10.3390/molecules25174009
pmc: PMC7504778
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Esters
0
Haptens
0
Protons
0
Morphine
76I7G6D29C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Magyar Tudományos Akadémia
ID : János Bolyai Research Scholarship
Organisme : Ministry for Innovation and Technology
ID : UNKP-19-4-SE-28
Organisme : National Research, Development and Innovation Office, Hungary
ID : NKFIH KH-130401
Organisme : National Research, Development and Innovation Office, Hungary
ID : VEKOP-2.3.3-15-2017-00020
Organisme : Emberi Eroforrások Minisztériuma
ID : 1783-3/2018/FEKUTSRAT
Références
J Med Chem. 2013 Feb 14;56(3):915-23
pubmed: 23249238
Eur J Pharmacol. 1976 Jul;38(1):149-56
pubmed: 954823
J Med Chem. 2011 Jul 28;54(14):5195-204
pubmed: 21692508
Cell Mol Life Sci. 2002 Oct;59(10):1681-9
pubmed: 12475179
Science. 1972 Jun 9;176(4039):1143-5
pubmed: 5064326
J Pharm Biomed Anal. 2017 Feb 20;135:97-105
pubmed: 28012310
J Endocrinol. 1975 Jan;64(1):6P-7P
pubmed: 1117229
Org Biomol Chem. 2014 Oct 7;12(37):7211-32
pubmed: 24995943
Science. 1970 Jun 12;168(3937):1347-8
pubmed: 5444264
Clin Immunol Immunopathol. 1974 Nov;3(2):155-70
pubmed: 4452223
Science. 1972 Nov 10;178(4061):647-8
pubmed: 5086404
J Am Chem Soc. 2017 Jun 28;139(25):8601-8611
pubmed: 28574716
Pharmacol Res Commun. 1976 Jun;8(3):325-35
pubmed: 800261
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):865-75
pubmed: 22229311
ChemistryOpen. 2019 Jul 04;8(7):879-887
pubmed: 31312587
Ther Adv Vaccines. 2014 Jul;2(4):106-17
pubmed: 24982760
AAPS PharmSciTech. 2019 Sep 16;20(8):314
pubmed: 31529175
J Pharm Biomed Anal. 2016 Oct 25;130:390-403
pubmed: 27066736
Proc Natl Acad Sci U S A. 1972 Jul;69(7):1835-7
pubmed: 4505662
Vaccine. 2006 Apr 12;24(16):3232-40
pubmed: 16494974
Nature. 1974 Dec 20;252(5485):708-10
pubmed: 4474602
J Immunol. 1973 Mar;110(3):667-73
pubmed: 4688917
J Pharm Biomed Anal. 2011 Apr 5;54(5):958-64
pubmed: 21168988
J Med Chem. 2012 Dec 13;55(23):10776-80
pubmed: 23134263
J Am Chem Soc. 2019 Feb 6;141(5):1798-1806
pubmed: 30532973
Clin Chem. 1981 Sep;27(9):1524-35
pubmed: 7261330
J Pharmacol Exp Ther. 2012 Apr;341(1):225-32
pubmed: 22262924
Vaccine. 2013 Jun 10;31(26):2804-10
pubmed: 23624097
Vaccine. 2012 Jun 29;30(31):4617-24
pubmed: 22583811
Chem Soc Rev. 2013 Jan 21;42(2):485-96
pubmed: 23099561